doi:10.3969/j.issn.1673-8640.2019.06.023

Abstract

CLC Number:

R446.1

. [J]. Laboratory Medicine, 2019, 34(6): 573-576.

Figures/Tables 1

References 25

[1]	POTHIWALA P,LEVINE S N.Analytic review:thyrotoxic periodic paralysis:a review[J]. J Intensive Care Med,2010,25(2):71-77.
[2]	KUNG A W.Clinical review:thyrotoxic periodic paralysis:a diagnostic challenge[J]. J Clin Endocrinol Metab,2006,91(7):2490-2495.
[3]	VIJAYAKUMAR A,ASHWATH G,THIMMAPPA D.Thyrotoxic periodic paralysis:clinical challenges[J]. J Thyroid Res,2014,2014:649502.
[4]	CHEN L,LANG D,RAN X W,et al.Clinical and molecular analysis of Chinese patients with thyrotoxic periodic paralysis[J]. Eur Neurol,2003,49(4):227-230.
[5]	SIGUIER F,LISSAC J,SAVOIE J C,et al.A case of acute thyrotoxicosis with flabby quadriplegia and paralysis of the pharyngo-laryngeal junction. Favorable course after thyroidectomy[J]. Presse Med,1970,78(14):657-659.
[6]	陈灏珠. 实用内科学[M]. 10版. 北京:人民卫生出版社,1997:802.
[7]	MIYASHITA Y,MONDEN T,YAMAMOTO K,et al.Ventricular fibrillation due to severe hypokalemia induced by steroid treatment in a patient with thyrotoxic periodic paralysis[J]. Intern Med,2006,45(1):11-13.
[8]	SOONTHORNPUN S,SETASUBAN W,THAMPRASIT A.Insulin resistance in subjects with a history of thyrotoxic periodic paralysis(TPP)[J]. Clin Endocrinol,2010,70(5):794-797.
[9]	YAO Y,FAN L,ZHANG X,et al.Episodes of paralysis in Chinese men with thyrotoxic periodic paralysis are associated with elevated serum testosterone[J]. Thyroid,2013,23(4):420-427.
[10]	BIERING H,BAUDITZ J,PIRLICH M,et al.Manifestation of thyrotoxic periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemia[J]. Horm Res,2003,59(6):301-304.
[11]	GUERRA M,RODRIGUEZ DEL CASTILLO A,BATTANER E,et al. Androgens stimulate preoptic area Na+,K+-ATPase activity in male rats[J]. Neurosci Lett,1987,78(1):97-100.
[12]	冉兴无,李秀钧,何钰珏,等. 甲亢伴与不伴低钾周期性麻痹患者血管紧张素和醛固酮水平的变化[J]. 华西医科大学学报,2001,32( 3):435-437.
[13]	GOLDBERGER Z D.Images in cardiovascular medicine. An electrocardiogram triad in thyrotoxic hypokalemic periodic paralysis[J]. Circulation,2007,115(6):e179-e180.
[14]	SHISHIBA Y.Recent progress on the searchs of pathogenesis of thyrotoxic periodic paralysis[J]. Nihon Rinsho,2006,64(12):2339-2347.
[15]	ROSS D S,BURCH H B,COOPER D S,et al.2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid,2016,26(10):1343-1421.
[16]	TASSONE H,MOULIN A,HENDERSON S O.The pitfalls of potassium replacement in thyrotoxic periodic paralysis:a case report and review of the literature[J]. J Emerg Med,2004,26(2):157-161.
[17]	任丽珏,张柱. 52例甲亢并低钾性周期性麻痹临床分析[J]. 中外医疗,2014,33(7):87-88.
[18]	王娜. 甲状腺功能亢进合并低钾性周期性麻痹的诱因分析及防治对策[J]. 医学综述,2015,21(4):742-743.
[19]	RYAN D P,DA SILVA M R,SOONG T W,et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis[J]. Cell,2010,140(1):88-98.
[20]	LI X,YAO S,XIANG Y,et al.The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis[J]. BMC Neurol,2015,15:1-6.
[21]	CHEUNG C L,LAU K S,HO A Y,et al.Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3[J]. Nat Genet,2012,44(9):1026-1029.
[22]	JONGJAROENPRASERT W,PHUSANTISAMPAN T,MAHASIRIMONGKOL S,et al.A genome-wide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemic periodic paralysis[J]. J Hum Genet,2012,57(5):301-304.
[23]	CHU P Y,CHENG C J,TSENG M H,et al.Genetic variant rs623011(17q24.3) associates with non-familial thyrotoxic and sporadic hypokalemic paralysis[J]. Clin Chim Acta,2012,414:105-108.
[24]	PARK S,KIM T Y,SIM S,et al.Association of KCNJ2 genetic variants with susceptibility to thyrotoxic periodic paralysis in patients with Graves' disease[J]. Exp Clin Endocrinol Diabetes,2016,125(2):75-78.
[25]	唐紫薇,姚渝,田浩明. KCNJ2基因下游rs312691、rs623011位点多态性与甲状腺功能毒症周期性瘫痪的关系[J]. 重庆医科大学学报,2015,40(9):1228-1231.

组别	例数	rs623011（A/G）			等位基因（A/G）频率	rs312691（C/T）			等位基因（C/T）频率
组别	例数	AA	AG	GG	等位基因（A/G）频率	CC	CT	TT	等位基因（C/T）频率
中国江西、贵州、陕西地区^[23]	229
TPP组	127	78	40	9	0.772	82	39	6	0.799
甲亢对照组	102	12	70	20	0.461	15	66	21	0.471
中国四川地区^[27]	333
健康对照组	94	34	39	21	0.431	27	33	34	0.463
甲亢组	127	48	60	19	0.386	20	63	44	0.406
TPP组	112	15	43	54	0.674	56	39	17	0.674
中国台湾地区^[26]	190
TPP组	90	6	35	49	0.739
健康对照组	100	26	41	33	0.535
中国香港地区^[23]	204
TPP组	122								0.760
健康对照组	82								0.450
组别	例数	rs623011（A/G）			等位基因（A/G）频率	rs312691（C/T）			等位基因（C/T）频率
组别	例数	AA	AG	GG	等位基因（A/G）频率	CC	CT	TT	等位基因（C/T）频率
韩国^[25]	83
TPP组	43					22	14	7	0.674
甲亢对照组	40					2	27	11	0.388
泰国^[24]	223
TPP组	103	62	35	6	0.772
甲亢对照组	120	26	56	38	0.450

组别	例数	rs623011（A/G）			等位基因（A/G）频率	rs312691（C/T）			等位基因（C/T）频率
组别	例数	AA	AG	GG	等位基因（A/G）频率	CC	CT	TT	等位基因（C/T）频率
中国江西、贵州、陕西地区^[23]	229
TPP组	127	78	40	9	0.772	82	39	6	0.799
甲亢对照组	102	12	70	20	0.461	15	66	21	0.471
中国四川地区^[27]	333
健康对照组	94	34	39	21	0.431	27	33	34	0.463
甲亢组	127	48	60	19	0.386	20	63	44	0.406
TPP组	112	15	43	54	0.674	56	39	17	0.674
中国台湾地区^[26]	190
TPP组	90	6	35	49	0.739
健康对照组	100	26	41	33	0.535
中国香港地区^[23]	204
TPP组	122								0.760
健康对照组	82								0.450
组别	例数	rs623011（A/G）			等位基因（A/G）频率	rs312691（C/T）			等位基因（C/T）频率
组别	例数	AA	AG	GG	等位基因（A/G）频率	CC	CT	TT	等位基因（C/T）频率
韩国^[25]	83
TPP组	43					22	14	7	0.674
甲亢对照组	40					2	27	11	0.388
泰国^[24]	223
TPP组	103	62	35	6	0.772
甲亢对照组	120	26	56	38	0.450

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 25

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.